Last reviewed · How we verify
Fecal Microbial Transplant Enema
At a glance
| Generic name | Fecal Microbial Transplant Enema |
|---|---|
| Sponsor | VA Office of Research and Development |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- FMT in Cirrhosis and Hepatic Encephalopathy (PHASE1, PHASE2)
- Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS) (PHASE3)
- Auto Fecal Microbial Transplant Post Helicobacter Pylori Antibiotic Therapy (PHASE1, PHASE2)
- Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection
- Faecal Bacteriotherapy for Postantibiotic Diarrhoea in Critically Ill Patients (NA)
- Safety and Efficacy of FMT in Individuals With One or More Recurrences of Clostridium Difficile Associated Disease (CDAD) (PHASE1, PHASE2)
- Autologous Fecal Microbiota Transplantation to Prevent Antibiotic Resistant Bacteria Colonization (PHASE1)
- Transfer of Healthy Gut Flora for Restoration of Intestinal Microbiota Via Enema for Patients in the Rehabilitative Phase of Malnutrition (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: